The BiliSeq molecular test developed at UPMC doubled detection sensitivity for bile duct cancer compared to standard pathology.
Key Details
- 1BiliSeq detected 82% of bile duct cancers vs. 44% with pathology alone in a six-year, multi-center study of over 2,000 patients.
- 2Combining BiliSeq with pathology increased detection up to 90% while minimizing false positives for benign disease.
- 3The test identifies actionable genetic mutations in about 20% of patients, informing care changes in nearly a third of those cases.
- 4BiliSeq maintains high performance in at-risk subgroups, detecting up to 86% of cancers in high-risk patients like those with PSC.
- 5Results have direct implications for diagnosis clarification and treatment—including transplant decisions—where imaging and standard biopsies often fail.
Why It Matters
This study demonstrates transformative potential for molecular diagnostics to support radiology and pathology in challenging cancer cases, reducing uncertainty for clinicians and patients. Enhanced diagnostic accuracy may lead to faster, more tailored interventions, especially in hard-to-assess biliary cancers.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.